Role of Autophagy in Type 2 Diabetes Microvascular Dysfunction

Description

The goal of this clinical trial is to examine the role of autophagy on microvascular function in adults with Type 2 Diabetes. The main question it aims to answer are: * Does presence of Type 2 Diabetes reduce autophagy and impair microvascular function? * Does exposure to high glucose impair autophagy and subsequently microvascular function? Participants will undergo 2 study days. The primary outcome will be in vivo microvascular function testing. Following the first study day participants will undergo either supplementation with trehalose, an autophagy activator, or placebo for 14 days. The second study day will test in vivo microvascular function.

Conditions

Type 2 Diabetes, Healthy Aging

Study Overview

Study Details

Study overview

The goal of this clinical trial is to examine the role of autophagy on microvascular function in adults with Type 2 Diabetes. The main question it aims to answer are: * Does presence of Type 2 Diabetes reduce autophagy and impair microvascular function? * Does exposure to high glucose impair autophagy and subsequently microvascular function? Participants will undergo 2 study days. The primary outcome will be in vivo microvascular function testing. Following the first study day participants will undergo either supplementation with trehalose, an autophagy activator, or placebo for 14 days. The second study day will test in vivo microvascular function.

Role of Autophagy in Type 2 Diabetes Microvascular Dysfunction

Role of Autophagy in Type 2 Diabetes Microvascular Dysfunction

Condition
Type 2 Diabetes
Intervention / Treatment

-

Contacts and Locations

Milwaukee

Medical College of Wisconsin, Milwaukee, Wisconsin, United States, 53226

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Clinical Diagnosis of Type 2 Diabetes Mellitus in accordance with American Diabetes Association (ADA) guidelines (Type 2 Diabetic group)
  • * Otherwise healthy individuals (Healthy control group) with no more than 1 cardiovascular risk factor
  • * Uncontrolled hypertension
  • * Current Tobacco use or within last 6 months
  • * BMI \> 35
  • * Hyperlipidemia
  • * Hypercholesterolemia
  • * Type 1 Diabetes
  • * Use of anti-coagulant drugs, or anti-platelet drugs
  • * Symptomatic coronary artery disease
  • * Heart Failure
  • * Renal Impairment
  • * Hormone Replacement Therapy
  • * History of Retinopathy
  • * Documented Neuromuscular Disorders
  • * Porphyria Cutanea Tarda (blistering of skin to sun; photosensitivity)
  • * Pregnancy (Young Female subjects)
  • * Allergies to Povidone Iodine
  • * Use Erectile Dysfunction Medication in the past 6 months
  • * Use of Topical/non-topical Steroids in last 6 months
  • * Active Anti-Cancer Treatment or Treatment within last 12 months
  • * Active COVID-19 or within the past 3 months
  • * Gender Reassignment Therapy

Ages Eligible for Study

18 Years to 80 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Medical College of Wisconsin,

William Hughes, Ph.D., PRINCIPAL_INVESTIGATOR, Medical College of Wisconsin

Study Record Dates

2029-12-31